DOES SPANKING VIOLATE THE NON-AGGRESSION PRINCIPLE?

"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug." Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...

“Love your enemies.”— Jesus Christ “I hate my opponent and I don’t want the best for them.”—President Trump This country was built on the radical idea that government exists to serve the people—not to control them, monitor them, manage them, or rule over them. That idea is being systematically dismantled by a Deep State determined to […]